All In MedTech

FDA Clearance Tracker · P130021-S058

Medtronic CoreValve™ Evolut™ R System and Medtronic CoreValve™ Evolut™ Pro System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 16, 2019 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P130021-S058
Device name
Medtronic CoreValve™ Evolut™ R System and Medtronic CoreValve™ Evolut™ Pro System
Applicant location
Miinneapolis, MN
Received
Mar 15, 2019
Decided
Aug 16, 2019
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P130021

Device type

Device class
Class III

Every decision under product code NPT

FDA's approval statement

As written in FDA's record.

Approval for the Medtronic CoreValve Evolut R System and Medtronic CoreValve Evolut PRO System for expanding the indication to include patients at low risk for surgical aortic valve replacement. The devices are indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, including a cardiac surgeon, to be appropriate for the transcatheter heart valve replacement therapy.

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.